摘要:
Compounds of the following backbone structure: which are useful as Tumor necrosis factor (TNF) inhibitors in treating disease related to elevated TNF.
摘要:
Compounds of formula (I) are described in which R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or optionally substituted heteroaryl; R3 is a group —L1—R7 or —L2—R8 [where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, —S(O)nR9, —NHSO2R9, —C(═Z)OR10, —C(═Z)R10, —OR10, —N(R11)—C(═Z)R9, —NY1Y2, —SO2NY1Y2, —C(═Z)—NY1Y2, —N(R11)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)R10, —C(═NOR10)R10, —C(═Z)NR10OR12, —N(R11)—C(═NR13)—NY1Y2 or —N(R11)—C(═Z)OR11; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl]; R4 is a group —L3—R14 [where L3 is a direct bond or an optionally substituted alkylene linkage and R14 is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy (or an acid bioisostere), cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, nitro, —NY4Y5, —N(R10)—C(═Z)—R15; —N(R10)—C(═Z)—L4—R16, —NH—C(═Z)—NH—R15, —NH—C(═Z)—NH—L4—R16, —N(R10)—SO2—R15, —N(R10)—SO2—L4—R16, —S(O)nR9, —C(═Z)—NY4Y5 or —C(═Z)—OR9]; R5 is hydrogen, alkyl or hydroxyalkyl; or R4 and R5, when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C═CH2; R6 is hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (I) and N-oxides thereof, and their prodrugs. The compounds are TNF inhibitors and are useful as pharmaceuticals.
摘要翻译:描述式(I)的化合物,其中R 1是任选取代的杂芳基; R2是任选取代的芳基或任选取代的杂芳基; R3是基团-L1-R7或-L2-R8 [其中L1是任选取代的亚烷基键; R 7是氢,芳基,氰基,环烷基,杂芳基,杂环烷基,硝基,-S(O)n R 9,-NHSO 2 R 9,-C(= Z)OR 10,-C(= Z)R 10,-OR 10,-N(R 11) -C(= Z)R9,-NY1Y2,-SO2NY1Y2,-C(= Z)-NY1Y2,-N(R11)-C(= Z)-NY1Y2,-N(OR10)-C(= Z)-NY1Y2 ,-N(OR 10)-C(= Z)R 10,-C(= NOR 10)R 10,-C(= Z)NR 10 OR 12,-N(R 11)-C(= NR 13)-NY 1 Y 2或-N(R 11) C(= Z)OR 11; L2是直接键或包含2至约6个碳原子并含有双或三碳 - 碳键的直链或支链碳链; 和R8是氢,芳基,环烯基,环烷基,杂芳基或杂环烷基]; R4是基团-L3-R14 [其中L3是直接键或任选取代的亚烷基键,R 14是氢,烷基,叠氮基,羟基,烷氧基,芳基,芳基烷氧基,芳氧基,羧基(或酸式生物电子等排体) 杂芳基烷氧基,杂芳氧基,杂环烷基,杂环烷氧基,硝基,-NY 4 Y 5,-N(R 10)-C(= Z)-R 15; -N(R10)-C(= Z)-L4-R
摘要:
This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R.sup.3 is halogen;R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl;R.sup.5 is carboxy or an acid isostere;X is oxygen or sulphur; andn is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.
摘要翻译:本发明涉及式Ⅰ化合物,其中R1是CN,CH2CN,CH = CHCN,CHO或CH = CHCO2H; R 2是芳基低级烷氧基,杂芳基低级烷氧基,芳基低级烷硫基或杂芳基低级烷硫基,其中芳基和杂芳基部分中的每一个任选被取代; R3是卤素; R 4是任选取代的芳基或任选取代的杂芳基; R5是羧基或酸等isostere; X是氧或硫; n为0或1; 或其N-氧化物,其前体药物溶剂化物或其药学上可接受的盐,该化合物具有内皮素拮抗剂活性。 本发明还涉及制备式I化合物及其药物用途的方法。
摘要:
This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R.sup.3 is halogen;R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl;R.sup.5 is carboxy or an acid isostere;X is oxygen or sulphur; andn is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.
摘要翻译:本发明涉及式Ⅰ化合物,其中R1是CN,CH2CN,CH = CHCN,CHO或CH = CHCO2H; R 2是芳基低级烷氧基,杂芳基低级烷氧基,芳基低级烷硫基或杂芳基低级烷硫基,其中芳基和杂芳基部分中的每一个任选被取代; R3是卤素; R 4是任选取代的芳基或任选取代的杂芳基; R5是羧基或酸等isostere; X是氧或硫; n为0或1; 或其N-氧化物,其前体药物溶剂化物或其药学上可接受的盐,该化合物具有内皮素拮抗剂活性。 本发明还涉及制备式I化合物及其药物用途的方法。
摘要:
The invention relates to a compound of formula (I), where: R1 is a phenyl group optionally substituted by one or more halogen atoms; R2 is: a hydrogen atom or a halogen atom or a cyano group; a —C(═O)Y group where Y is a hydrogen atom, or a —NH2 or —OR3 group; a —C(═S)NH2 group; a —C(═NH)NH—OH group; a —CH2OH or —CH2F group; a —CH═N—OH group; a —CH═CH2 or —C═C—R3 group; a H or H R1 group being a hydrogen or (C1-C4)alkyl group; R3 is a hydrogen atom or (C1-C4)alkyl group; and R4 is a —NH2, (C1-C4)alkyl, (C1-C4)fluoroalkyl or (C3-C7)cycloalkyl group.
摘要:
Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.
摘要:
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
摘要:
Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.
摘要:
Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.
摘要:
The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors.